Abstract: The purpose of the present invention is to provide: a method for testing the aggravation risk for a person infected with the COVID-19 virus, the method allowing the use of urine as a test sample; a test kit for the method; and a companion diagnostic drug and an aggravation risk marker thereof. The present invention is a method that includes a step for determining the amount of liver fatty acid binding protein in urine sampled from a subject, and that tests the aggravation risk of SARS-CoV-2 infectious disease (COVID-19) on the basis of the quantitative determination result.

Abstract: Provided are a method and a kit for quantifying L-FABP or oxidized L-FABP in any sample, a method and a kit for testing for kidney diseases on the basis of the quantifying result of L-FABP or oxidized L-FABP in urine of a subject, and a companion diagnostic drug. This method for quantifying liver type fatty acid binding protein includes a step for promoting an antigen-antibody reaction, and quantifying the liver type fatty acid binding protein under a condition in which the measurement sensitivity of oxidized liver type fatty acid binding protein is higher than that of unoxidized liver type fatty acid binding protein.

Abstract: The purpose of the present invention is to provide: a liver-type fatty acid-binding protein standard by which, in a measurement using a specifically binding substance, the range of variation of a measured value caused by a liver-type fatty acid-binding protein can be narrowed; a method of evaluating the standard; a method of drawing a calibration curve of a liver-type fatty acid-binding protein; and a method of quantifying the protein. A liver-type fatty acid-binding protein standard in which a coefficient of change in oxidation, said coefficient being represented by the ratio of a measured value obtained by using a liver-type fatty acid-binding protein standard having been subjected to an oxidation treatment with 10 mM of an oxidant for 1 hour at 25° C. to a measured value obtained by using the liver-type fatty acid-binding protein standard not subjected to the oxidation treatment, is set to 1.

Abstract: The purpose of the present invention is to provide: a liver-type fatty acid-binding protein standard by which, in a measurement using a specifically binding substance, the range of variation of a measured value caused by a liver-type fatty acid-binding protein can be narrowed; a method of evaluating the standard; a method of drawing a calibration curve of a liver-type fatty acid-binding protein; and a method of quantifying the protein. A liver-type fatty acid-binding protein standard in which a coefficient of change in oxidation, said coefficient being represented by the ratio of a measured value obtained by using a liver-type fatty acid-binding protein standard having been subjected to an oxidation treatment with 10 mM of an oxidant for 1 hour at 25° C. to a measured value obtained by using the liver-type fatty acid-binding protein standard not subjected to the oxidation treatment, is set to 1.

Abstract: Disclosed are: a prognosis diagnosis method which can diagnose the prognosis of a patient suffering from sepsis or sepsis-related multiple organ failure in a simple manner and with high accuracy and a prognosis diagnosis kit for use in the prognosis diagnosis method. The prognosis diagnosis method comprises: a first detection step of detecting a liver fatty acid-binding protein contained in urine collected from a subject with a specific antibody; a second detection step of treating the urine with a Redox reagent such as hemin and detecting a liver fatty acid-binding protein contained in the treated urine with the specific antibody; and a comparison step of comparing a detection value obtained in the first step with a detection value obtained in the second step. It is determined that the larger the detection value obtained in the second step compared to that in the first step, the worse the prognosis.

Abstract: Disclosed are: a prognosis diagnosis method which can diagnose the prognosis of a patient suffering from sepsis or sepsis-related multiple organ failure in a simple manner and with high accuracy and a prognosis diagnosis kit for use in the prognosis diagnosis method. The prognosis diagnosis method comprises: a first detection step of detecting a liver fatty acid-binding protein contained in urine collected from a subject with a specific antibody; a second detection step of treating the urine with a Redox reagent such as hemin and detecting a liver fatty acid-binding protein contained in the treated urine with the specific antibody; and a comparison step of comparing a detection value obtained in the first step with a detection value obtained in the second step. It is determined that the larger the detection value obtained in the second step compared to that in the first step, the worse the prognosis.

Abstract: The present invention provides a method for malaria testing which enables testing for the presence of malaria infection and the extent of the infection in a convenient manner; and a reagent or kit which can be used in the method. The method for malaria testing according to the present invention includes the step of detecting a liver-type fatty acid binding protein present in urine collected from a subject animal. The extent of infection is determined to be higher when a larger amount of the liver-type fatty acid binding protein is present in a test sample.

Abstract: It is intended to provide a method for noninvasively isolating human renal stem/progenitor cells, an isolated renal stem/progenitor cells, a therapeutic agent for renal disease, mouse mesenchymal cells which can be used for isolating human renal stem/progenitor cells and a culture supernatant of the same. Renal stem/progenitor cells are isolated by primarily culturing cells contained in the urine of a patient having renal disease in a medium containing mouse mesenchymal cells identified by the deposition number of FERM ABP-10865 or a culture supernatant of the same, staining the obtained primarily cultured cells with Hoechst 33342 and separating a weak-positive or negative fraction.

Abstract: The present invention provides a method for malaria testing which enables testing for the presence of malaria infection and the extent of the infection in a convenient manner; and a reagent or kit which can be used in the method. The method for malaria testing according to the present invention includes the step of detecting a liver-type fatty acid binding protein present in urine collected from a subject animal. The extent of infection is determined to be higher when a larger amount of the liver-type fatty acid binding protein is present in a test sample.

Abstract: Method for examining kidney disease, which comprises detecting fatty acid binding protein derived from kidney tissues, which is present in specimen collected from mammal excluding Rodents. By the present method, it is possible to obtain test results, which may be very important information for diagnosis or prognosis of kidney disease that has been very difficult in the past. Based on test results obtained by the present method, it may be possible to select a suitable method for treatment of kidney disease with taking into consideration risks such as the prognosis, etc. Besides, the present method can be applied to, in addition to the kidney disease samples, urine samples as well, so that the examination procedure can be simple and efficient.

Abstract: Method for examining kidney disease, which comprises detecting fatty acid binding protein derived from kidney tissues, which is present in specimen collected from mammal excluding Rodents. By the present method, it is possible to obtain test results which may be very important information for diagnosis of prognosis of kidney disease, that has been very difficult in the past. Based on test results obtained by the present method, it may be possible to select a suitable method for treatment of kidney disease with taking into consideration risks as to the prognosis, etc. Besides, the present method can be applied to, in addition to the kidney tissue samples, urine samples as well, so that the examination procedure can be simple and efficient.

Abstract: The present invention provides a method for screening or identifying therapeutic or prophylactic agents for renal diseases, which comprises assaying a test substance for the activity of up-regulating the expression of fatty acid-binding protein (FABP), and novel mouse proximal renal tubular epithelial cell lines useful therein. The present invention also provides therapeutic or prophylactic agents for renal diseases comprising, as an active ingredient, an agent having activity of up-regulating FABP expression; agents for up-regulating the expression of FABP, and for treating or preventing renal diseases, which comprise a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist or carnitine palmitoyltransferase (CPT) inhibitor or the like.

Abstract: The present invention provides a method for screening or identifying therapeutic or prophylactic agents for renal diseases, which comprises assaying a test substance for the activity of up-regulating the expression of fatty acid-binding protein (FABP), and novel mouse proximal renal tubular epithelial cell lines useful therein. The present invention also provides therapeutic or prophylactic agents for renal diseases comprising, as an active ingredient, an agent having activity of up-regulating FABP expression; agents for up-regulating the expression of FABP, and for treating or preventing renal diseases, which comprise a compound having activity of peroxisome proliferator-activated receptor (PPAR) agonist or carnitine palmitoyltransferase (CPT) inhibitor or the like.

Abstract: A synthetic fiber which is excellent in moisture-absorbing/releasing property and exhibits high elongation and high stretch recovery, characterized in that it has moisture absorption ratios of 0.5 to 4.0% by weight in environments of 20° C.×65% RH and that of 4.5% by weight or more in environments of 30° C.×90% RH, respectively, and also has a difference between the absorption ratios in both the environments of 4.0% by weight or more. The representative examples of such fibers include polyurethane synthetic fiber and polyether synthetic fiber. The synthetic fiber maintains a high strength at break of an elastic fiber component thereof also in the state of having absorbed moisture, is excellent in color fastness to rubbing, and can be used for manufacturing a stretch fiber fabric product excellent in comfort through blending with another fiber material.

Abstract: Disclosed is a polyurethaneurea elastic fiber composed of a polyurethaneurea obtained by a reaction of a polymer diol, organic diisocyanate, bifunctional amine mainly consisting of 75% or more of ethylenediamine and a monoamine; and incorporated therein a specific alkylsulfonate or sulfate having a specific hydrocarbon groups containing carbon atoms ranging from 6 to 20. The polyurethaneurea elastic fiber can exhibit a high breaking strength and high elongation at break, and therefore, can produce a fine denier polyurethaneurea elastic fiber. The fiber can provide a converting processing of elastic fiber under a high draft and at a higher processing speed.